<?xml version="1.0" encoding="UTF-8"?>
<p>We demonstrated before that VGCV prevents the mortality and morbidity of Ad5-infected hamsters when administered therapeutically, i.e., after virus challenge [
 <xref rid="B25-viruses-09-00147" ref-type="bibr">25</xref>]. To determine whether VGCV is similarly active against Ad6 infection, we infected immunosuppressed hamsters i.v. with 2 Ã— 10
 <sup>10</sup> PFU/kg of Ad6, and treated the animals with 200 mg/kg of VGCV starting one day after challenge, and continued the treatment b.i.d. for the duration of the study.
</p>
